{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:32:01Z","timestamp":1788402721684,"version":"build-2803163510"},"reference-count":119,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"abstract":"<jats:p>Autosomal Dominant Polycystic Kidney Disease (ADPKD) leads to end stage kidney disease (ESKD) through the development and expansion of multiple cysts throughout the kidney parenchyma. An increase in cyclic adenosine monophosphate (cAMP) plays an important role in generating and maintaining fluid-filled cysts because cAMP activates protein kinase A (PKA) and stimulates epithelial chloride secretion through the cystic fibrosis transmembrane conductance regulator (CFTR). A vasopressin V2 receptor antagonist, Tolvaptan, was recently approved for the treatment of ADPKD patients at high risk of progression. However additional treatments are urgently needed due to the poor tolerability, the unfavorable safety profile, and the high cost of Tolvaptan. In ADPKD kidneys, alterations of multiple metabolic pathways termed metabolic reprogramming has been consistently reported to support the growth of rapidly proliferating cystic cells. Published data suggest that upregulated mTOR and c-Myc repress oxidative metabolism while enhancing glycolytic flux and lactic acid production. mTOR and c-Myc are activated by PKA\/MEK\/ERK signaling so it is possible that cAMPK\/PKA signaling will be upstream regulators of metabolic reprogramming. Novel therapeutics opportunities targeting metabolic reprogramming may avoid or minimize the side effects that are dose limiting in the clinic and improve on the efficacy observed in human ADPKD with Tolvaptan.<\/jats:p>","DOI":"10.3389\/fmolb.2023.1126055","type":"journal-article","created":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T06:30:28Z","timestamp":1676529028000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Metabolism-based approaches for autosomal dominant polycystic kidney disease"],"prefix":"10.3389","volume":"10","author":[{"given":"Ivona","family":"Bakaj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Pocai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1093\/ckj\/sfac029","article-title":"Sodium-glucose cotransporter inhibition in polycystic kidney disease: Fact or fiction","volume":"15","author":"Afsar","year":"2022","journal-title":"Clin. Kidney J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1111\/cts.13202","article-title":"Pharmacokinetics of bempedoic acid in patients with renal impairment","volume":"15","author":"Amore","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1007\/s40265-022-01745-9","article-title":"Drugs in clinical development to treat autosomal dominant polycystic kidney disease","volume":"82","author":"Bais","year":"2022","journal-title":"Drugs"},{"key":"B4","doi-asserted-by":"publisher","first-page":"6629","DOI":"10.1038\/s41598-021-84609-8","article-title":"Metabolic profiling in children and young adults with autosomal dominant polycystic kidney disease","volume":"11","author":"Baliga","year":"2021","journal-title":"Sci. Rep."},{"key":"B5","doi-asserted-by":"publisher","first-page":"E410","DOI":"10.1152\/ajpendo.00042.2009","article-title":"Glucagon acts in a dominant manner to repress insulin-induced mammalian target of rapamycin complex 1 signaling in perfused rat liver","volume":"297","author":"Baum","year":"2009","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"B6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1517\/13543781003588491","article-title":"Novel targets for the treatment of autosomal dominant polycystic kidney disease","volume":"19","author":"Belibi","year":"2010","journal-title":"Expert. Opin. Investig. Drugs."},{"key":"B7","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1111\/j.1523-1755.2004.00843.x","article-title":"Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells","volume":"66","author":"Belibi","year":"2004","journal-title":"Kidney Int."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1093\/ckj\/sfaa232","article-title":"A randomized phase 1b cross-over study of the safety of low-dose pioglitazone for treatment of autosomal dominant polycystic kidney disease","volume":"14","author":"Blazer-Yost","year":"2021","journal-title":"Clin. Kidney J."},{"key":"B9","doi-asserted-by":"publisher","first-page":"274376","DOI":"10.1155\/2010\/274376","article-title":"Pioglitazone attenuates cystic burden in the PCK rodent model of polycystic kidney disease","volume":"2010","author":"Blazer-Yost","year":"2010","journal-title":"PPAR Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1001\/jama.2020.14775","article-title":"Sleeve gastrectomy","volume":"324","author":"Brajcich","year":"2020","journal-title":"JAMA."},{"key":"B11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2174\/1573402113666170427142815","article-title":"Effect of statin therapy on the progression of autosomal dominant polycystic kidney disease. A secondary analysis of the halt PKD trials","volume":"13","author":"Brosnahan","year":"2017","journal-title":"Curr. Hypertens. Rev."},{"key":"B12","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: Established and emerging indications","volume":"398","author":"Brown","year":"2021","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3390\/kidneydial2020020","article-title":"Ren.Nu, a dietary program for individuals with autosomal-dominant polycystic kidney disease implementing a sustainable, plant-focused, kidney-safe, ketogenic approach with avoidance of renal stressors","volume":"2","author":"Bruen","year":"2022","journal-title":"Kidney Dial."},{"key":"B14","doi-asserted-by":"publisher","first-page":"889","DOI":"10.2215\/CJN.08350813","article-title":"Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease","volume":"9","author":"Cadnapaphornchai","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1111\/j.1600-6143.2010.03152.x","article-title":"Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: What is the appropriate serum level?","volume":"10","author":"Canaud","year":"2010","journal-title":"Am. J. Transpl."},{"key":"B16","doi-asserted-by":"publisher","first-page":"753418","DOI":"10.3389\/fmed.2022.753418","article-title":"AMPK and polycystic kidney disease drug development: An interesting off-target target","volume":"9","author":"Caplan","year":"2022","journal-title":"Front. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40620-021-01062-6","article-title":"Therapeutic advances in ADPKD: The future awaits","volume":"35","author":"Capuano","year":"","journal-title":"J. Nephrol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.5414\/CN110510","article-title":"Tolvaptan vs. somatostatin in the treatment of ADPKD: A review of the literature","volume":"97","author":"Capuano","year":"","journal-title":"Clin. Nephrol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ekir.2017.01.010","article-title":"Bariatric surgery and kidney-related outcomes","volume":"2","author":"Chang","year":"2017","journal-title":"Kidney Int. Rep."},{"key":"B20","doi-asserted-by":"publisher","first-page":"7161","DOI":"10.1038\/s41598-017-07300-x","article-title":"Metformin inhibits cyst formation in a zebrafish model of polycystin-2 deficiency","volume":"7","author":"Chang","year":"2017","journal-title":"Sci. Rep."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1093\/hmg\/ddab340","article-title":"Metformin induces lactate accumulation and accelerates renal cyst progression in Pkd1-deficient mice","volume":"31","author":"Chang","year":"2022","journal-title":"Hum. Mol. Genet."},{"key":"B23","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nrneph.2015.39","article-title":"Vasopressin and disruption of calcium signalling in polycystic kidney disease","volume":"11","author":"Chebib","year":"2015","journal-title":"Nat. Rev. Nephrol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1053\/j.ajkd.2020.12.020","article-title":"Assessing risk of rapid progression in autosomal dominant polycystic kidney disease and special considerations for disease-modifying therapy","volume":"78","author":"Chebib","year":"2021","journal-title":"Am. J. Kidney Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1681\/ASN.2015030231","article-title":"2-Deoxy-d-Glucose ameliorates PKD progression","volume":"27","author":"Chiaravalli","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S0140-6736(22)01545-8","article-title":"Effect of statin therapy on muscle symptoms: An individual participant data meta-analysis of large-scale, randomised, double-blind trials","volume":"400","year":"2022","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"278","DOI":"10.7861\/clinmedicine.9-3-278","article-title":"Autosomal dominant polycystic kidney disease","volume":"9","author":"Chow","year":"2009","journal-title":"Clin. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/bip.22072","article-title":"Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents","volume":"98","author":"Day","year":"2012","journal-title":"Biopolymers"},{"key":"B29","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41581-021-00393-8","article-title":"Pathophysiology of diabetic kidney disease: Impact of SGLT2 inhibitors","volume":"17","author":"DeFronzo","year":"2021","journal-title":"Nat. Rev. Nephrol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"5704","DOI":"10.1038\/s41598-018-23732-5","article-title":"Activation of Calcium-Sensing Receptor increases intracellular calcium and decreases cAMP and mTOR in PKD1 deficient cells","volume":"8","author":"Di Mise","year":"2018","journal-title":"Sci. Rep."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e21874","DOI":"10.1096\/fj.202100774R","article-title":"Pre-clinical evaluation of dual targeting of the GPCRs CaSR and V2R as therapeutic strategy for autosomal dominant polycystic kidney disease","volume":"35","author":"Di Mise","year":"2021","journal-title":"FASEB J."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1128\/MCB.01259-08","article-title":"Polycystin-1 regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1","volume":"29","author":"Distefano","year":"2009","journal-title":"Mol. Cell. Biol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3109\/00365590903359908","article-title":"Effect of pravastatin on kidney function and urinary protein excretion in autosomal dominant polycystic kidney disease","volume":"44","author":"Fassett","year":"2010","journal-title":"Scand. J. Urology Nephrol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1053\/ajkd.2002.33379","article-title":"Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: A longitudinal study","volume":"39","author":"Fick-Brosnahan","year":"2002","journal-title":"Am. J. Kidney Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1515\/jtim-2016-0028","article-title":"Inhibition of cyst growth in PCK and Wpk rat models of polycystic kidney disease with low doses of peroxisome proliferator-activated receptor \u03b3 agonists","volume":"4","author":"Flaig","year":"2016","journal-title":"J. Transl. Int. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/s0272-6386(12)80051-5","article-title":"Autosomal dominant polycystic kidney disease--more than a renal disease","volume":"16","author":"Gabow","year":"1990","journal-title":"Am. J. Kidney Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/s41581-019-0155-2","article-title":"International consensus statement on the diagnosis and management of autosomal dominant polycystic kidney disease in children and young people","volume":"15","author":"Gimpel","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"B39","first-page":"14","article-title":"Diabetes and dyslipidemia","volume":"2","author":"Ginsberg","year":"2001","journal-title":"Heart. Fail. Monit."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e032620","DOI":"10.1136\/bmjopen-2019-032620","article-title":"Long-acting somatostatin analogue treatments in autosomal dominant polycystic kidney disease and polycystic liver disease: A systematic review and meta-analysis","volume":"10","author":"Griffiths","year":"2020","journal-title":"B.M.J. Open."},{"key":"B41","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.molcel.2008.03.003","article-title":"AMPK phosphorylation of raptor mediates a metabolic checkpoint","volume":"30","author":"Gwinn","year":"2008","journal-title":"Mol. Cell."},{"key":"B42","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3945\/ajcn.116.133561","article-title":"Energy expenditure and body composition changes after an isocaloric ketogenic diet in overweight and obese men","volume":"104","author":"Hall","year":"2016","journal-title":"Am. J. Clin. Nutr."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1001941","DOI":"10.3389\/fmolb.2022.1001941","article-title":"Beneficial effects of bempedoic acid treatment in polycystic kidney disease cells and mice","volume":"9","author":"Hallows","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"B44","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev.med.60.101707.125712","article-title":"Polycystic kidney disease","volume":"60","author":"Harris","year":"2009","journal-title":"Annu. Rev. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"103697","DOI":"10.1016\/j.isci.2021.103697","article-title":"Weight loss and cystic disease progression in autosomal dominant polycystic kidney disease","volume":"25","author":"Hopp","year":"2021","journal-title":"iScience"},{"key":"B46","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41569-019-0201-6","article-title":"Targeting ATP citrate lyase to reduce LDL cholesterol","volume":"16","author":"Huynh","year":"2019","journal-title":"Nat. Rev. Cardiol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/s0092-8674(03)00929-2","article-title":"TSC2 mediates cellular energy response to control cell growth and survival","volume":"115","author":"Inoki","year":"2003","journal-title":"Cell"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e0125603","DOI":"10.1371\/journal.pone.0125603","article-title":"Effect of sodium-glucose cotransport inhibition on polycystic kidney disease progression in PCK rats","volume":"10","author":"Kapoor","year":"2015","journal-title":"PLoS One"},{"key":"B49","doi-asserted-by":"publisher","first-page":"F726","DOI":"10.1152\/ajprenal.00551.2015","article-title":"A mild reduction of food intake slows disease progression in an orthologous mouse model of polycystic kidney disease","volume":"310","author":"Kipp","year":"2016","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1093\/ckj\/sfab112","article-title":"The association of glucagon with disease severity and progression in patients with autosomal dominant polycystic kidney disease: An observational cohort study","volume":"14","author":"Knol","year":"2021","journal-title":"Clin. Kidney J."},{"key":"B51","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrc3038","article-title":"Otto Warburg's contributions to current concepts of cancer metabolism","volume":"11","author":"Koppenol","year":"2011","journal-title":"Nat. Rev. Cancer."},{"key":"B52","doi-asserted-by":"publisher","first-page":"736","DOI":"10.2967\/jnumed.106.038679","article-title":"GLP-1 receptor expression in human tumors and human normal tissues: Potential for in vivo targeting","volume":"48","author":"K\u00f6rner","year":"2007","journal-title":"J. Nucl. Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1074\/jbc.M111.303594","article-title":"Suppression of G\u03b1s synthesis by simvastatin treatment of vascular endothelial cells","volume":"287","author":"Kou","year":"2012","journal-title":"J. Biol. Chem."},{"key":"B54","doi-asserted-by":"publisher","first-page":"4765","DOI":"10.1038\/s41467-022-32543-2","article-title":"PKD1 and PKD2 mRNA cis-inhibition drives polycystic kidney disease progression","volume":"13","author":"Lakhia","year":"2022","journal-title":"Nat. Commun."},{"key":"B55","doi-asserted-by":"publisher","first-page":"F122","DOI":"10.1152\/ajprenal.00352.2017","article-title":"PPAR\u03b1 agonist fenofibrate enhances fatty acid \u03b2-oxidation and attenuates polycystic kidney and liver disease in mice","volume":"314","author":"Lakhia","year":"2018","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s11892-019-1270-y","article-title":"Thiazolidinediones: The forgotten diabetes medications","volume":"19","author":"Lebovitz","year":"2019","journal-title":"Curr. Diab. Rep."},{"key":"B57","doi-asserted-by":"publisher","first-page":"4148","DOI":"10.1038\/s41467-019-11918-y","article-title":"Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease","volume":"10","author":"Lee","year":"2019","journal-title":"Nat. Commun."},{"key":"B58","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/febs.13139","article-title":"ATP-citrate lyase regulates cellular senescence via an AMPK- and p53-dependent pathway","volume":"282","author":"Lee","year":"2015","journal-title":"Febs. J."},{"key":"B59","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ebiom.2019.08.041","article-title":"Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease","volume":"47","author":"Leonhard","year":"2019","journal-title":"EBioMedicine"},{"key":"B60","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/bph.14558","article-title":"The combination of metformin and 2-deoxyglucose significantly inhibits cyst formation in miniature pigs with polycystic kidney disease","volume":"176","author":"Lian","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s11255-019-02292-1","article-title":"Use of mammalian target of rapamycin inhibitors in patient with autosomal dominant polycystic kidney disease: An updated meta-analysis","volume":"51","author":"Lin","year":"2019","journal-title":"Int. Urol. Nephrol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"109468","DOI":"10.1016\/j.cellsig.2019.109468","article-title":"The PI3K\/Akt\/mTOR pathway in polycystic kidney disease: A complex interaction with polycystins and primary cilium","volume":"66","author":"Margaria","year":"2020","journal-title":"Cell Signal"},{"key":"B63","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1001\/jama.2018.15870","article-title":"Effect of Lanreotide on kidney function in patients with autosomal dominant polycystic kidney disease: The DIPAK 1 randomized clinical trial","volume":"320","author":"Meijer","year":"2018","journal-title":"JAMA"},{"key":"B64","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1055\/s-0034-1397344","article-title":"Overview of microRNA biology","volume":"35","author":"Mohr","year":"2015","journal-title":"Semin. Liver Dis."},{"key":"B65","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1093\/ndt\/gfab312","article-title":"An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: Consensus statement on behalf of the ERA working group on inherited kidney disorders, the European rare kidney disease reference network and polycystic kidney disease international","volume":"37","author":"M\u00fcller","year":"2022","journal-title":"Nephrol. Dial. Transpl."},{"key":"B66","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol. Metab."},{"key":"B67","doi-asserted-by":"publisher","first-page":"F1166","DOI":"10.1152\/ajprenal.00196.2007","article-title":"Vasopressin V2 receptor expression along rat, mouse, and human renal epithelia with focus on TAL","volume":"293","author":"Mutig","year":"2007","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1126\/science.aah5582","article-title":"Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy","volume":"357","author":"Myers","year":"2017","journal-title":"Science"},{"key":"B69","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/nm.2171","article-title":"Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models","volume":"16","author":"Natoli","year":"2010","journal-title":"Nat. Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/ng1076","article-title":"Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells","volume":"33","author":"Nauli","year":"2003","journal-title":"Nat. Genet."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B72","doi-asserted-by":"publisher","first-page":"908","DOI":"10.2215\/CJN.16871020","article-title":"Overweight and obesity and progression of ADPKD","volume":"16","author":"Nowak","year":"2021","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1681\/ASN.2017070819","article-title":"Overweight and obesity are predictors of Pro.gression in early autosomal dominant polycystic kidney disease","volume":"29","author":"Nowak","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/ndt\/gfac061.011","article-title":"MO016: Feasibility and effectiveness of short-term ketogenic interventions in autosomal dominant polycystic kidney disease (ADPKD): Results from the reset-pkd study","volume":"37","author":"Oehm","year":"","journal-title":"Nephrol. Dial. Transpl."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ndt\/gfac311","article-title":"RESET-PKD: A pilot trial on short-term ketogenic interventions in autosomal dominant polycystic kidney disease","author":"Oehm","year":"","journal-title":"Nephrol. Dial. Transplant"},{"key":"B76","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.kint.2021.07.021","article-title":"TAMEing ADPKD with metformin: Safe and effective?","volume":"100","author":"Ong","year":"2021","journal-title":"Kidney Int."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1093\/ckj\/sfac103","article-title":"Can ketogenic dietary interventions slow disease progression in ADPKD: What we know and what we don't","volume":"15","author":"Ong","year":"2022","journal-title":"Clin. Kidney J."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1681\/ASN.2022010053","article-title":"Channel function of polycystin-2 in the endoplasmic reticulum protects against autosomal dominant polycystic kidney disease","volume":"33","author":"Padhy","year":"2022","journal-title":"J. Am. Soc. Nephrol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/s41581-018-0051-1","article-title":"Metabolism and mitochondria in polycystic kidney disease research and therapy","volume":"14","author":"Padovano","year":"2018","journal-title":"Nat. Rev. Nephrol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"F27","DOI":"10.1152\/ajprenal.00298.2021","article-title":"Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model","volume":"322","author":"Pastor-Soler","year":"2022","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"10786","DOI":"10.1038\/ncomms10786","article-title":"mTORC1-mediated inhibition of polycystin-1 expression drives renal cyst formation in tuberous sclerosis complex","volume":"7","author":"Pema","year":"2016","journal-title":"Nat. Commun."},{"key":"B82","doi-asserted-by":"publisher","first-page":"e1002777","DOI":"10.1371\/journal.pmed.1002777","article-title":"Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (aladin 2): A randomized, double-blind, placebo-controlled, multicenter trial","volume":"16","author":"Perico","year":"2019","journal-title":"PLoS Med."},{"key":"B83","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.kint.2021.06.013","article-title":"Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD)","volume":"100","author":"Perrone","year":"2021","journal-title":"Kidney Int."},{"key":"B84","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/nrneph.2015.128","article-title":"Vascular complications in autosomal dominant polycystic kidney disease","volume":"11","author":"Perrone","year":"2015","journal-title":"Nat. Rev. Nephrol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"13457","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nat. Commun."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1681\/ASN.2015010047","article-title":"Phosphodiesterase isoform regulation of cell proliferation and fluid secretion in autosomal dominant polycystic kidney disease","volume":"27","author":"Pinto","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.2337\/db09-0278","article-title":"Glucagon-like peptide 1\/glucagon receptor dual agonism reverses obesity in mice","volume":"58","author":"Pocai","year":"2009","journal-title":"Diabetes"},{"key":"B88","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1530\/JOE-12-0368","article-title":"Unraveling oxyntomodulin, GLP1's enigmatic brother","volume":"215","author":"Pocai","year":"2012","journal-title":"J. Endocrinol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"109495","DOI":"10.1016\/j.cellsig.2019.109495","article-title":"Metabolic reprogramming and the role of mitochondria in polycystic kidney disease","volume":"67","author":"Podrini","year":"2020","journal-title":"Cell Signal"},{"key":"B90","doi-asserted-by":"publisher","first-page":"4651","DOI":"10.3390\/nu14214651","article-title":"Dietary aspects and drug-related side effects in autosomal dominant polycystic kidney disease progression","volume":"14","author":"Quiroga","year":"2022","journal-title":"Nutrients"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B92","doi-asserted-by":"publisher","first-page":"e0146654","DOI":"10.1371\/journal.pone.0146654","article-title":"Inhibition of aerobic glycolysis attenuates disease progression in polycystic kidney disease","volume":"11","author":"Riwanto","year":"2016","journal-title":"PLoS One"},{"key":"B93","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1159\/000368540","article-title":"Inhibition of sodium-glucose cotransporter 2 with dapagliflozin in han: SPRD rats with polycystic kidney disease","volume":"40","author":"Rodriguez","year":"2015","journal-title":"Kidney Blood Press. Res."},{"key":"B94","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/nm.3092","article-title":"Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy","volume":"19","author":"Rowe","year":"2013","journal-title":"Nat. Med."},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.18103\/mra.v10i12.3232","article-title":"Octreotide lar in patients with autosomal dominant polycystic kidney disease: From bench to a novel perspective of therapy","volume":"10","author":"Ruggenenti","year":"2022","journal-title":"Med. Res. Arch."},{"key":"B96","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s11883-022-01054-2","article-title":"Bempedoic acid: For whom and when","volume":"24","author":"Ruscica","year":"2022","journal-title":"Curr. Atheroscler. Rep."},{"key":"B97","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.diabet.2018.06.005","article-title":"SGLT2 inhibition and glucagon secretion in humans","volume":"44","author":"Saponaro","year":"2018","journal-title":"Diabetes Metab."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.34067\/KID.0004002020","article-title":"Baseline characteristics and patient-reported outcomes of ADPKD patients in the multicenter TAME-PKD clinical trial","volume":"1","author":"Seliger","year":"2020","journal-title":"Kidney360."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1093\/ndt\/gfz109","article-title":"Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney disease","volume":"35","author":"Soomro","year":"2020","journal-title":"Nephrol. Dial. Transpl."},{"key":"B100","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3390\/biomedicines9010089","article-title":"The biology of vasopressin","volume":"9","author":"Sparapani","year":"2021","journal-title":"Biomedicines"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-022-00547-x","article-title":"New insights into activation and function of the AMPK","author":"Steinberg","year":"2022","journal-title":"Nat. Rev. Mol. Cell. Biol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1093\/ckj\/sfab162","article-title":"Ketogenic dietary interventions in autosomal dominant polycystic kidney disease-a retrospective case series study: First insights into feasibility, safety and effects","volume":"15","author":"Strubl","year":"2021","journal-title":"Clin. Kidney J."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1002\/2211-5463.13459","article-title":"PF-06409577 inhibits renal cyst progression by concurrently inhibiting the mTOR pathway and CFTR channel activity","volume":"12","author":"Su","year":"2022","journal-title":"FEBS Open Bio"},{"key":"B104","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1681\/ASN.V95903","article-title":"Chloride and fluid secretion in polycystic kidney disease","volume":"9","author":"Sullivan","year":"1998","journal-title":"J. Am. Soc. Nephrol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1161\/CIRCULATIONAHA.106.630194","article-title":"Statins activate AMP-activated protein kinase in vitro and in vivo","volume":"114","author":"Sun","year":"2006","journal-title":"Circulation"},{"key":"B106","doi-asserted-by":"publisher","first-page":"e0257606","DOI":"10.1371\/journal.pone.0257606","article-title":"Somatostatin analog therapy effectiveness on the progression of polycystic kidney and liver disease: A systematic review and meta-analysis of randomized clinical trials","volume":"16","author":"Suwabe","year":"2021","journal-title":"PLoS One"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.bbadis.2010.11.014","article-title":"Polycystic kidney disease: Pathogenesis and potential therapies","volume":"1812","author":"Takiar","year":"2011","journal-title":"Biochim. Biophys. Acta."},{"key":"B108","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1073\/pnas.1011498108","article-title":"Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis","volume":"108","author":"Takiar","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B109","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s40620-019-00679-y","article-title":"ADPKD current management and ongoing trials","volume":"33","author":"Testa","year":"2020","journal-title":"J. Nephrol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.cmet.2019.09.012","article-title":"Ketosis ameliorates renal cyst growth in polycystic kidney disease","volume":"30","author":"Torres","year":"","journal-title":"Cell. Metab."},{"key":"B111","doi-asserted-by":"publisher","first-page":"4506","DOI":"10.1172\/JCI128503","article-title":"Crystal deposition triggers tubule dilation that accelerates cystogenesis in polycystic kidney disease","volume":"129","author":"Torres","year":"","journal-title":"J. Clin. Invest."},{"key":"B112","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","article-title":"Autosomal dominant polycystic kidney disease","volume":"369","author":"Torres","year":"2007","journal-title":"Lancet"},{"key":"B114","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1093\/ndt\/16.11.2152","article-title":"Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease","volume":"16","author":"van Dijk","year":"2001","journal-title":"Nephrol. Dial. Transpl."},{"key":"B115","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1681\/ASN.2015020132","article-title":"Food restriction ameliorates the development of polycystic kidney disease","volume":"27","author":"Warner","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"E26","DOI":"10.1152\/ajpendo.00555.2019","article-title":"Glucagon-Dependent suppression of mTORC1 is associated with upregulation of hepatic FGF21 mRNA translation","volume":"319","author":"Welles","year":"2020","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"B117","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00109-017-1606-5","article-title":"\u03b2-Arrestin-1 deficiency ameliorates renal interstitial fibrosis by blocking Wnt1\/\u03b2-catenin signaling in mice","volume":"96","author":"Xu","year":"2018","journal-title":"J. Mol. Med."},{"key":"B118","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1159\/000509087","article-title":"Effect of statins on renal function and total kidney volume in autosomal dominant polycystic kidney disease","volume":"6","author":"Xue","year":"2020","journal-title":"Kidney Dis. (Basel)"},{"key":"B119","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1046\/j.1523-1755.2003.00023.x","article-title":"Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys","volume":"63","author":"Yamaguchi","year":"2003","journal-title":"Kidney Int."},{"key":"B120","doi-asserted-by":"publisher","first-page":"981963","DOI":"10.3389\/fmolb.2022.981963","article-title":"Emerging therapies for autosomal dominant polycystic kidney disease with a focus on cAMP signaling","volume":"9","author":"Zhou","year":"2022","journal-title":"Front. Mol. Biosci."}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2023.1126055\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T06:30:32Z","timestamp":1676529032000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2023.1126055\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,16]]},"references-count":119,"alternative-id":["10.3389\/fmolb.2023.1126055"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2023.1126055","relation":{},"ISSN":["2296-889X"],"issn-type":[{"value":"2296-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,16]]},"article-number":"1126055"}}